Table 2.
Comparison of Percentage of Patients Meeting Quality Measures, 2015–2016 Versus 2017–2018
| |
|
2015–2016 |
2017–2018 |
|
|
All observationsa |
|---|---|---|---|---|---|---|
| Total number of observations |
2273 |
2723 |
|
|
4996 |
|
| Type | Measure | n (%) | n (%) | Change (pp), % | pb | n (%) |
| Process | Ever pneumococcal conjugate vaccine | 2080 (91.5) | 2566 (94.2) | 2.7 | <0.001 | 4646 (93.0) |
| Process | Ever pneumococcal polysaccharide vaccine | 2002 (88.1) | 2541 (93.3) | 5.2 | <0.001 | 4543 (90.9) |
| Process | 1 influenza vaccine during study period | 1843 (81.1) | 2243 (82.4) | 1.3 | 0.089 | 4086 (81.8) |
| Process | 1 face-to-face visit and 1 ID visit (any type) in each year | 1656 (72.9) | 2067 (75.9) | 3.1 | 0.014 | 3723 (74.5) |
| Process | 1 syphilis screening during study period | 1930 (84.9) | 2443 (89.7) | 4.8 | <0.001 | 4373 (87.5) |
| Process | 1 gonorrhea/chlamydia screening during study period | 1691 (74.4) | 2159 (79.3) | 4.9 | <0.001 | 3850 (77.1) |
| Process | ART prescription fill; 1 in each year | 1870 (82.3) | 2350 (86.3) | 4.0 | <0.001 | 4220 (84.5) |
| Outcome | HIV RNA <200 copies/mL at last measure; 1 in each year | 1608 (70.7) | 2115 (77.7) | 6.9 | <0.001 | 3723 (74.5) |
| Outcome | Not hospitalized during study period | 1966 (86.5) | 2359 (86.6) | 0.1 | 0.984 | 4325 (86.6) |
| Outcome | No ED visit during study period | 1779 (78.3) | 2128 (78.1) | −0.1 | 0.777 | 3907 (78.2) |
| Outcome | Nonsmoker at last visit | 1850 (81.4) | 2232 (82.0) | 0.6 | 0.152 | 4082 (81.7) |
| Outcome | Systolic BP <140 mmHg at last measure | 1902 (83.7) | 2219 (81.5) | −2.2 | 0.014 | 4121 (82.5) |
| Outcome | Diastolic BP <90 mmHg at last measure | 2073 (91.2) | 2471 (90.7) | −0.5 | 0.344 | 4544 (91.0) |
| Outcome | No new diagnosis of depression during study period | 2050 (90.2) | 2459 (90.3) | 0.1 | 0.807 | 4509 (90.3) |
| Outcome | 15 < BMI <30 kg/m2 at last measure | 1412 (62.1) | 1596 (58.6) | −3.5 | <0.001 | 3008 (60.2) |
| Outcome | Hemoglobin ≥12 g/dL at last measure | 1913 (84.2) | 2278 (83.7) | −0.5 | 0.287 | 4191 (83.9) |
| Outcome | Blood sugar <140 mg/dL at last measure (random or fasting) | 2008 (88.3) | 2395 (88.0) | −0.4 | 0.304 | 4403 (88.1) |
| Outcome | ALT <51 U/L at last measure | 1956 (86.1) | 2458 (90.3) | 4.2 | <0.001 | 4414 (88.4) |
| Outcome | eGFR >60 mL/min/1.73 m2 at last measure | 1968 (86.6) | 2331 (85.6) | −1.0 | 0.004 | 4299 (86.0) |
| Outcome | LDL <130 mg/dL at last measure (fasting or direct) | 1542 (67.8) | 1905 (70.0) | 2.1 | 0.051 | 3447 (69.0) |
| Process | All process measure met | 892 (39.2) | 1384 (50.8) | 11.6 | <0.001 | 2276 (45.6) |
| Outcome | All outcome measures metc | 423 (18.6) | 555 (20.4) | 1.8 | 0.077 | 978 (19.6) |
| All | All quality measures metc | 224 (9.9) | 364 (13.4) | 3.5 | <0.001 | 588 (11.8) |
a
A total of 1878 patients are included in both 2015–2016 and 2017–2018 cohorts, and therefore contribute two observations each.
b
Significance level p < 0.05. GEE is used to account for patients included in both time periods.
c
Excludes BMI.
ALT, alanine aminotransferase; ART, antiretroviral treatment; BMI, body mass index; BP, blood pressure; ED, emergency department; eGFR, estimated glomerular filtration rate; GEE, generalized estimating equations; ID, infectious disease; LDL, low-density lipoprotein; pp, percentage points.